All In Biotech

Drug Trial Radar · NCT05183646

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)

Last checked: Nov 19, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

May 30, 2022

Primary completion

Dec 2029

Study completion Dec 2029

Sponsor

Lead sponsor
Dimerix Bioscience Pty LtdIndustry
Sponsor type
Industry
First posted
Jan 10, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with FSGS who are being treated with an ARB. Given the rarity of the disease and the similarities between adults and pediatric patients with FSGS, Dimerix will also investigate the efficacy and safety of DMX 200 in adolescents aged 12 to 17 years. The double-blind period will be followed by an open-label extension (OLE) which aims to assess the long-term efficacy and safety of DMX 200 for up to 2 additional years.

Conditions

  • FSGS

Interventions

  • DMX-200Drug

    DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor.

  • PlaceboDrug

    Patients will receive 120 mg capsules of Placebo twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the efficacy of DMX-200 in terms of urine protein/creatinine ratio (PCR) in patients with FSGS who are receiving an ARB.Time frame: Baseline to Week 35
  2. Evaluate the efficacy of DMX-200 in terms of estimated glomerular filtration rate (eGFR) slope in patients with FSGS who are receiving an ARB (Analysis at week 35 and Week 104).Time frame: Baseline to Week 104
  3. OLE - Assess the long-term safety and tolerability of open-label treatment with DMX-200 in patients with FSGS who are receiving an ARB.Time frame: Double-blind baseline to Week 216

Locations

220 sites in 21 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Active not recruiting

  • Phoenix Children's Hospital

    Phoenix, Arizona · Recruiting

  • Arizona Kidney Disease and Hypertension Center

    Phoenix, Arizona · Active not recruiting

  • Loma Linda University Medical Center

    Loma Linda, California · Active not recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • University of California, Los Angeles

    Los Angeles, California · Recruiting

  • Amicis Research Centre

    Northridge, California · Active not recruiting

  • Northridge Clinical Research Inc.

    Northridge, California · Active not recruiting

  • Kaiser Permanente

    Oakland, California · Recruiting

  • University of California Davis Health System

    Sacramento, California · Recruiting

  • Scripps Health

    San Diego, California · Active not recruiting

  • Stanford Hospital and Clinic

    Stanford, California · Recruiting

  • University of Colorado Anschutz Medical Campus

    Denver, Colorado · Recruiting

  • Denver Nephrology Research Division

    Denver, Colorado · Recruiting

  • South Florida Nephrology Group, P.A.

    Coral Springs, Florida · Active not recruiting

  • Nicklaus Children's Hospital

    Miami, Florida · Recruiting

  • CTR Oakwater LLC

    Orlando, Florida · Recruiting

  • Emory University School of Medicine

    Atlanta, Georgia · Recruiting

  • Georgia Nephrology

    Lawrenceville, Georgia · Active not recruiting

  • Boise Kidney

    Boise, Idaho · Active not recruiting

  • CARE Institute - Idaho Falls

    Idaho Falls, Idaho · Active not recruiting

  • University of Chicago

    Chicago, Illinois · Active not recruiting

  • NorthShore University HealthSystem

    Evanston, Illinois · Active not recruiting

  • Nephrology Associates of Northern Illinois and Indiana (NANI Research)

    Oak Brook, Illinois · Active not recruiting

  • University of Louisville

    Louisville, Kentucky · Active not recruiting

  • The Johns Hopkins Hospital

    Baltimore, Maryland · Active not recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Intermed Consultants

    Edina, Minnesota · Active not recruiting

  • University of Minnesota

    Minneapolis, Minnesota · Recruiting

  • CARE Institute - Nephrology & Hypertension Associates

    Tupelo, Mississippi · Active not recruiting

  • Children's Mercy Research Institute

    Kansas City, Missouri · Recruiting

  • Washington University, School of Medicine

    St Louis, Missouri · Recruiting

  • Somnos Clinical Research

    Lincoln, Nebraska · Active not recruiting

  • Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Renal Medicine Associates

    Albuquerque, New Mexico · Active not recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • University of North Carolina

    Chapel Hill, North Carolina · Recruiting

  • Atrium Health

    Charlotte, North Carolina · Recruiting

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio · Active not recruiting

  • Cleveland Clinic

    Cleveland, Ohio · Active not recruiting

Showing 40 of 220 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.